✨ Onyx Newsroom Recursion announced that CEO and President Najat Khan will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and that management will also participate in the 28th Annual Needham Growth Conference on January 16, 2026. The appearances provide investors with continued access to
✨ Onyx Summary DemeRx, Inc. reported positive Phase 1 multiple ascending dose results for DMX-1001, showing the oral noribogaine candidate was safe, well-tolerated, and exhibited pharmacokinetics that support advancement into Phase 2 trials for alcohol use disorder. The data position DemeRx, Inc. to progress a differentiated neurorestorative approach in a treatment
✨ Onyx Summary 3T Biosciences appointed Behzad Kharabi, M.D., as chief medical officer and Parker Institute for Cancer Immunotherapy CEO Karen E. Knudsen, Ph.D., MBA, to its board of directors as it advances its bispecific T-cell engager pipeline for solid tumors. The additions strengthen the company’s clinical development
✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the J.P. Morgan Healthcare Conference on January 14, 2026, highlighting the company’s autoimmune-focused cell therapy strategy to the investment community. The presentation signals Kyverna’s continued engagement with global healthcare investors as it advances its clinical
✨ Onyx Summary Rocket Pharmaceuticals, Inc. announced that CEO Gaurav Shah will present and host investor meetings at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The appearance provides investors with an update opportunity as the company advances multiple late- and early-stage gene therapy
✨ Onyx Summary ImmunityBio announced that OncoDaily has named its founder and executive chairman, Patrick Soon-Shiong, to The 100 Most Influential People in Oncology in 2025. The recognition underscores Soon-Shiong’s long-standing impact on oncology research and leadership, reinforcing ImmunityBio’s scientific credibility and visibility within the global cancer research and
✨ Onyx Summary Guardant Health said it will present and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12. The presentation provides the company with exposure to a major healthcare investment audience through a live and archived webcast
✨ Onyx Summary enGene Holdings Inc. reported full-year 2025 financial results and a business update, highlighting completion of enrollment in the pivotal LEGEND cohort for detalimogene in BCG-unresponsive NMIBC and a cash position of $342.4 million, extending operating runway into the second half of 2028. The company outlined plans to
✨ Onyx Summary Sinaptica Therapeutics announced the completion of its Scientific Advisory Board, assembling experts across neuroscience, clinical development, neuromodulation, patient advocacy, and commercialization to guide the company through its upcoming pivotal Alzheimer’s disease trial. The expanded board strengthens Sinaptica’s strategic positioning at a key inflection point, supporting clinical
✨ Onyx Summary A consortium led by Verily secured a two-year, $9.2 million renewal of the NIH System Biology award to advance FAIRplex, a platform enabling researchers to find, access, and analyze multimodal data from Accelerating Medicines Partnership (AMP®) projects. The renewal shifts FAIRplex from initial development to operational deployment
✨ Onyx Summary Geron Corporation granted stock options covering 320,000 shares to a newly hired employee as an inducement award, with options priced at the December 17, 2025 closing share price and vesting over four years in accordance with Nasdaq rules and the company’s inducement equity plan. FOSTER CITY,
✨ Onyx Summary Perspective Therapeutics announced that Chief Executive Officer Thijs Spoor will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. SEATTLE, Dec. 18, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering
✨ Onyx Summary Kyverna Therapeutics priced an underwritten public offering of 13.33 million shares at $7.50 per share, generating expected gross proceeds of approximately $100 million, with an option for underwriters to purchase up to an additional 2.0 million shares. The offering, led by J.P. Morgan, Leerink
✨ Onyx Summary Legend Biotech Corporation announced that CEO Ying Huang will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and replay available via the company’s investor relations website. SOMERSET, N.J.,Dec. 17, 2025 – Legend Biotech
✨ Onyx Summary ImmunityBio reported long-term Phase 2/3 QUILT-3.032 data showing that ANKTIVA plus BCG delivered durable disease-free, progression-free, and disease-specific survival, with high cystectomy avoidance through 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. Published in The Journal of Urology, the findings extend evidence
✨ Onyx Summary nChroma Bio said it has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of CRMA-1001 for the treatment of chronic hepatitis B. The approval advances a novel epigenetic silencing approach into the clinic, positioning the company to address a large unmet global
